Dr. Kevin Latinis, MD, PhD. with CoreMedica’s Christina Pierce, on site at Cass County hotspot doing COVID-19 Antibody testing blood collection.
CoreMedica Providing COVID-19 Antibody Testing for Hotspot Mitigation
May 14, 2020 — Lee’s Summit, MO. CoreMedica laboratories, Inc. (CoreMedica) announced today its strategy of mitigating hot-spots through collaboration with the COVID-19 Task Force in Cass County using CoreMedica’s COVID-19 Antibody Screening Test which uses finger-stick collected capillary blood samples for detection of antibodies (IgG/IgM) developed in response to the Novel Coronavirus (SARS-CoV-2). This antibody test is designed to identify, and track population spread of virus exposure and to identify asymptomatic carriers likely not having been tested by PCR-based molecular assays. In addition to identifying and predicting convalescent immunity, this antibody test is also designed to track population spread of virus exposure and to identify asymptomatic carriers whom likely have not been tested by PCR-based molecular assays and are at high risk to continue to infect others.
The Hotspot Mitigation program in cooperation with local government authorities is currently being utilized by Missouri nursing homes in Cass, St. Charles and St. Louis counties as well as for First Responders in Cass County. Current testing results have identified the expanding prevalence of the disease with initial data from testing 550 people showing 11.8% IgG positives and 4.4% IgM positives. Further, early in the testing roll out the Task Force was able to find 60% IgM positive individuals in Cass County that were asymptomatic, still working in high risk environments and when identified for viral testing were found to be PCR positive.
Cass County, MO.
Antibody tests performed = 415
IgG Positive = 44 / IgG Positive Rate = 8.7%
IgM Positive = 15 / IgM Positive Rate = 4.1%
IgM asymptomatic Carriers = 33%
St. Louis County, MO.
Antibody tests performed = 100
IgG Positive = 12 / IgG Positive Rate = 12%
IgM Positive = 3 / IgM Positive Rate = 3%
IgM asymptomatic Carriers = 67%
St. Charles County, MO.
Antibody tests performed = 35
IgG Positive = 17 / IgG Positive Rate = 48.6%
IgM Positive = 4 / IgM Positive Rate = 11.4%
IgM asymptomatic Carriers = 100%
Features and benefits of CoreMedica’s COVID-19 Antibody Screening Test include
- Identify IgM positive individuals to direct for immediate viral testing in combination with Hot Spot mitigation strategy to virally test only symptomatic individuals
- Detect antibodies generated in response to virus infection (Antibody IgG/IgM).
- Uses only 4 drops of blood.
- Reduces risk of exposure to others.
- High throughput testing relative to viral or antigen based virus detection techniques.
Dr. Kevin Latinis, MD, PhD, of Latinis Rheumatology and Scientific Advisor for the Cass County COVID-19 Task Force. “As a clinician who understands immunological-based diseases as well as a scientist with the training in basic immunology research, I realized there was a local need to help out the COVID-19 testing crisis. In a synchronistic opportunity, I found a company that could deliver a product to allow me to rapidly identify and mitigate risk in a targeted nursing home hotspot. I am very proud of the hard work of this collaborative effort from the scientists and executive and employed staff at all levels at this company. They put their primary effort into saving lives in the Kansas City community. We have successfully accomplished my immediate goal and now we have to get on with bigger things and reopen the economy.“
Cory Zuehlsdorf, Chief Operating Officer and Director of CoreMedica’s North America operations shares, “CoreMedica was founded on the premise that blood analysis should be convenient and accessible so that more individuals can have insights into their health. Now more than ever individuals need access to testing to understand their SARS-CoV-2 immunity status and make informed decisions about their health. Cass County is at the forefront in our collaboration to test as many fellow Missourians as possible. To launch this effort and begin testing locally in our own backyard was our first and foremost priority.”
For more information please contact us at 816.425.1690 or email firstname.lastname@example.org.